Cancer Cytopathology

Cover image for Vol. 123 Issue 8

August 2015

Volume 123, Issue 8

Pages i–iv, 445–505

  1. Issue Information

    1. Top of page
    2. Issue Information
    3. CytoSource
    4. Cytopathology Help Desk
    5. Commentary
    6. Review Articles
    7. Original Articles
    8. Information Item
    1. You have free access to this content
      Issue information (pages i–iv)

      Article first published online: 14 AUG 2015 | DOI: 10.1002/cncy.21602

  2. CytoSource

    1. Top of page
    2. Issue Information
    3. CytoSource
    4. Cytopathology Help Desk
    5. Commentary
    6. Review Articles
    7. Original Articles
    8. Information Item
    1. You have free access to this content
  3. Cytopathology Help Desk

    1. Top of page
    2. Issue Information
    3. CytoSource
    4. Cytopathology Help Desk
    5. Commentary
    6. Review Articles
    7. Original Articles
    8. Information Item
  4. Commentary

    1. Top of page
    2. Issue Information
    3. CytoSource
    4. Cytopathology Help Desk
    5. Commentary
    6. Review Articles
    7. Original Articles
    8. Information Item
    1. You have free access to this content
      Comments on the recently published “Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma” (pages 449–453)

      Anders Hjerpe and Katalin Dobra

      Article first published online: 10 JUN 2015 | DOI: 10.1002/cncy.21563

      Recently published guidelines describe how a specific diagnosis based on effusions can be obtained in most patients with malignant mesothelioma. The high positive predictive value makes biopsy sampling redundant in these patients and allows an earlier diagnosis.

  5. Review Articles

    1. Top of page
    2. Issue Information
    3. CytoSource
    4. Cytopathology Help Desk
    5. Commentary
    6. Review Articles
    7. Original Articles
    8. Information Item
    1. Molecular markers: Implications for cytopathology and specimen collection (pages 454–460)

      Paul A. VanderLaan

      Article first published online: 11 MAY 2015 | DOI: 10.1002/cncy.21560

      In this era of personalized medicine, testing for a wide array of relevant molecular markers has become an increasingly important component in the diagnostic, prognostic, and therapeutic workup of cytology specimens. The recognition of these established and emerging molecular markers by cytopathologists is an important step toward realizing the promise of personalized medicine.

  6. Original Articles

    1. Top of page
    2. Issue Information
    3. CytoSource
    4. Cytopathology Help Desk
    5. Commentary
    6. Review Articles
    7. Original Articles
    8. Information Item
    1. Digital gene expression profiling of a series of cytologically indeterminate thyroid nodules (pages 461–470)

      Riccardo Giannini, Liborio Torregrossa, Stefano Gottardi, Lorenzo Fregoli, Nicla Borrelli, Mauro Savino, Elisabetta Macerola, Paolo Vitti, Paolo Miccoli and Fulvio Basolo

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncy.21564

      Gene expression profiling may improve diagnostic accuracy in indeterminate fine-needle aspiration cytology samples. The current data suggest that preoperative gene expression profiling may be helpful in the classification of thyroid nodules.

    2. Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing (pages 471–479)

      Svetlana Paskaš, Jelena Janković, Vladan Živaljević, Svetislav Tatić, Vesna Božić, Aleksandra Nikolić, Dragica Radojković, Svetlana Savin and Dubravka Cvejić

      Article first published online: 27 APR 2015 | DOI: 10.1002/cncy.21554

      Based on the BRAF V600E mutation status, galectin-3 protein expression, and microRNA-221/222 expression, a predictor model distinguishing benign fine-needle aspiration samples with indeterminate cytology from malignant ones has been developed.

    3. Poor cell block adequacy rate for molecular testing improved with the addition of Diff-Quik–stained smears: Need for better cell block processing (pages 480–487)

      Shuko Harada, Emmanuel Agosto-Arroyo, Jessica A. Levesque, Evan Alston, Karen M. Janowski, Gina M. Coshatt and Isam A. Eltoum

      Article first published online: 8 MAY 2015 | DOI: 10.1002/cncy.21561

      The objective of this study is to assess the frequency and types of samples deemed insufficient for lung cancer molecular testing (quantity not sufficient [QNS]). For cases rejected for the inadequacy of cell blocks of cytology specimens, air-dried, Diff-Quik–stained smears have been reviewed and used. The QNS rate for small biopsy specimens is 35.9% (28 of 78), whereas 64% (16 of 25) of cytology cases ordered on CBs are rejected. In combination with Diff-Quik–stained smears, the QNS rate for cytology specimens is 32% (8 of 25). The utilization of Diff-Quik–stained smears for molecular testing has improved the adequacy of cytologic samples, and it provides a minimally invasive alternative to surgical biopsy for molecular analysis.

    4. The impact of the new proposed Papanicolaou Society of Cytopathology terminology for pancreaticobiliary cytology in endoscopic US-FNA: A single-Institutional experience (pages 488–494)

      Mauro Ajaj Saieg, Valerie Munson, Shanna Colletti and Aziza Nassar

      Article first published online: 20 MAY 2015 | DOI: 10.1002/cncy.21559

      The application of the new proposed terminology for pancreaticobiliary cytology has a greater impact on specimens previously classified as atypical and suspicious. Its broad use may ultimately contribute to a more standardized therapy for patients with pancreatic disease.

    5. Cytopathologic features of epithelioid inflammatory myofibroblastic sarcoma with correlation of histopathology, immunohistochemistry, and molecular cytogenetic analysis (pages 495–504)

      Jen-Chieh Lee, Jiann-Ming Wu, Jau-Yu Liau, Hsuan-Ying Huang, Cheng-Yu Lo, I-Shiow Jan, Jason L. Hornick and Xiaohua Qian

      Article first published online: 2 JUL 2015 | DOI: 10.1002/cncy.21558

      Epithelioid inflammatory myofibroblastic sarcoma is an aggressive variant of inflammatory myofibroblastic tumor. The cytologic features recapitulate its histologic characteristics. Diagnosis requires a high index of suspicion as well as confirmatory immunohistochemistry and molecular studies.

  7. Information Item

    1. Top of page
    2. Issue Information
    3. CytoSource
    4. Cytopathology Help Desk
    5. Commentary
    6. Review Articles
    7. Original Articles
    8. Information Item
    1. You have free access to this content

SEARCH

SEARCH BY CITATION